Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia’s Parliament Shoots Down Pharma Cost Recovery Bill; Lilly Closes In On Diabetes Reimbursement In NZ: Australia/New Zealand Regulatory Roundup

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Medicines Australia applauded the defeat in Australia's parliament Aug. 28 of the National Health Amendment, which included a cost-recovery mechanism that would have put the onus on drug makers to fund the process for listing medicines on Australia's Pharmaceutical Benefits Scheme

You may also be interested in...



New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup

PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1

PharmAsia News Australia/New Zealand Roundup: Medicines Australia, PHARMAC, Helicon, Pharmaxis

Medicines Australia Critical Of Labor Government's First Budget

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel